| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has …
Over the last 12 months, insiders at Arcturus Therapeutics Holdings Inc. have bought $0 and sold $0 worth of Arcturus Therapeutics Holdings Inc. stock.
On average, over the past 5 years, insiders at Arcturus Therapeutics Holdings Inc. have bought $71,522 and sold $2.59M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,238 shares for transaction amount of $20,499 was made by SASSINE ANDY (Chief Financial Officer) on 2025‑08‑15.
| 2025-08-15 | SASSINE ANDY | Chief Financial Officer | 1,238 0.0039% | $16.56 | $20,499 | -61.24% | ||
| 2024-10-15 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 12,000 0.0423% | $20.76 | $249,121 | -23.03% | |
| 2024-06-12 | Sale | SASSINE ANDY | Chief Financial Officer | 50,000 0.1838% | $32.03 | $1.6M | -42.95% | |
| 2024-06-05 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 114 0.0004% | $45.00 | $5,130 | -59.64% | |
| 2024-06-03 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 26,000 0.095% | $40.01 | $1.04M | -55.87% | |
| 2024-03-25 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 17,435 0.0652% | $35.02 | $610,574 | -40.76% | |
| 2024-03-19 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 8,565 0.033% | $35.01 | $299,839 | -38.71% | |
| 2023-11-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0187% | $18.72 | $93,602 | +40.76% | |
| 2023-10-02 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0188% | $25.61 | $128,062 | +2.96% | |
| 2023-09-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0187% | $31.45 | $157,264 | -13.91% | |
| 2023-08-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0184% | $34.91 | $174,550 | -15.95% | |
| 2023-07-14 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 25,000 0.093% | $35.01 | $875,250 | -13.94% | |
| 2023-07-14 | Sale | Kummerfeld Keith C | See Remarks | 6,968 0.0259% | $35.00 | $243,880 | -13.94% | |
| 2023-07-03 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0189% | $28.75 | $143,750 | +7.43% | |
| 2023-06-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0189% | $27.16 | $135,800 | +11.30% | |
| 2023-05-11 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 7,925 0.0279% | $30.24 | $239,652 | -9.46% | |
| 2023-05-10 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 17,075 0.0656% | $30.00 | $512,250 | -0.36% | |
| 2023-05-01 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0187% | $25.93 | $129,650 | +12.31% | |
| 2023-04-18 | Sale | Kummerfeld Keith C | See Remarks | 6,968 0.0265% | $28.18 | $196,358 | +5.22% | |
| 2023-04-03 | Sale | Chivukula Pad | Chief Scientific Officer & COO | 5,000 0.0186% | $25.38 | $126,900 | +11.56% |
| Payne Joseph E | President and CEO | 1480097 5.2074% | $14.12M | 3 | 0 | +43.7% |
| SASSINE ANDY | Chief Financial Officer | 221764 0.7802% | $2.12M | 5 | 1 | +125.55% |
| FARRELL PETER C | director | 42955 0.1511% | $409,790.70 | 2 | 0 | +21.56% |
| Marquet Magda | director | 24942 0.0878% | $237,946.68 | 2 | 0 | +34.72% |
| Kummerfeld Keith C | See Remarks | 950 0.0033% | $9,063.00 | 2 | 2 | +40.68% |
$60,836,085 | 69 | 0.45% | $255.44M | |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$109,019,806 | 28 | 7.37% | $263.86M | |
$3,668,031 | 23 | 2.05% | $243.03M |
| Increased Positions | 66 | +34.74% | 5M | +18.52% |
| Decreased Positions | 85 | -44.74% | 7M | -26.9% |
| New Positions | 28 | New | 1M | New |
| Sold Out Positions | 49 | Sold Out | 3M | Sold Out |
| Total Postitions | 171 | -10% | 24M | -8.38% |
| Federated Hermes, Inc. | $29,338.00 | 16.77% | 4.69M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $16,029.00 | 9.16% | 2.56M | -76,624 | -2.9% | 2025-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | $12,174.00 | 6.96% | 1.95M | +115,368 | +6.3% | 2025-09-30 |
| Amova Asset Management Americas, Inc. | $12,174.00 | 6.96% | 1.95M | +117,632 | +6.43% | 2025-09-30 |
| Vanguard Group Inc | $11,785.00 | 6.73% | 1.89M | +75,440 | +4.17% | 2025-09-30 |
| Ark Investment Management Llc | $11,705.00 | 6.69% | 1.87M | +157,681 | +9.19% | 2025-09-30 |
| State Street Corp | $6,536.00 | 3.74% | 1.05M | +25,907 | +2.54% | 2025-09-30 |
| Balyasny Asset Management L.P. | $6,031.00 | 3.45% | 964,985 | +100,889 | +11.68% | 2025-09-30 |
| Morgan Stanley | $4,405.00 | 2.52% | 704,878 | +101,282 | +16.78% | 2025-09-30 |
| Schonfeld Strategic Advisors Llc | $4,174.00 | 2.38% | 667,827 | -116,580 | -14.86% | 2025-09-30 |